Markus Fischer

Markus Fischer

Auto-generated profile, based on publicly available information

Markus Fischer

University Hospital Leipzig

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Bioinformatics Advances
Verified
Journal Article
Open access
PDF file
SCSebastian Canzler
Sebastian Canzler
MFMarkus Fischer
Markus Fischer
DUDavid Ulbricht
David Ulbricht
NRNikola Ristic
Nikola Ristic
PHPeter W Hildebrand
Peter W Hildebrand
RSRené Staritzbichler
René Staritzbichler
Motivation: Protein–protein interactions (PPIs) play an essential role in a great variety of cellular processes and are therefore of significant interest for the design of new therapeutic compounds as well as the identification of side effects due to unexpected binding. Here, we present ProteinPrompt, a webserver that uses machine learning algorithms to calculate specific, currently unknown PPIs. Our tool is designed to quickly and reliably predict contact propensities based on an input sequence in order to scan large sequence libraries for potential binding partners, with the goal to accelerate and assure the quality of the laborious process of drug target identification. Results: We collected and thoroughly filtered a comprehensive database of known binders from several sources, which is available as download. ProteinPrompt provides two complementary search methods of similar accuracy for comparison and consensus building. The default method is a random forest (RF) algorithm that uses the auto-correlations of seven amino acid scales. Alternatively, a graph neural network (GNN) implementation can be selected. Additionally, a consensus prediction is available. For each query sequence, potential binding partners are identified from a protein sequence database. The proteom of several organisms are available and can be searched for binders. To evaluate the predictive power of the algorithms, we prepared a test dataset that was rigorously filtered for redundancy. No sequence pairs similar to the ones used for training were included in this dataset. With this challenging dataset, the RF method achieved an accuracy rate of 0.88 and an area under the curve of 0.95. The GNN achieved an accuracy rate of 0.86 using the same dataset. Since the underlying learning approaches are unrelated, comparing the results of RF and GNNs reduces the likelihood of errors. The consensus reached an accuracy of 0.89. Availability and implementation: ProteinPrompt is available online at: http://proteinformatics.org/ProteinPrompt, where training and test data used to optimize the methods are also available. The server makes it possible to scan the human proteome for potential binding partners of an input sequence within minutes. For local offline usage, we furthermore created a ProteinPrompt Docker image which allows for batch submission: https://gitlab.hzdr.de/proteinprompt/ProteinPrompt. In conclusion, we offer a fast, accurate, easy-to-use online service for predicting binding partners from an input sequence.

29 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MLMeike Luck
Meike Luck
MFMarkus Fischer
Markus Fischer
MWMaximilian Werle
Maximilian Werle
HSHolger A Scheidt
Holger A Scheidt
PMPeter Müller
Peter Müller
Small-molecule protein kinase inhibitors are used for the treatment of various diseases. Although their effect(s) on the respective kinase are generally quite well understood, surprisingly, their interaction with membranes is only barely investigated; even though these drugs necessarily come into contact with the plasma and intracellular membranes. Using biophysical methods such as NMR, ESR, and fluorescence spectroscopy in combination with lipid vesicles, we studied the membrane interaction of the kinase inhibitors sunitinib, erlotinib, idelalisib, and lenvatinib; these drugs are characterized by medium log p values, a parameter reflecting the overall hydrophobicity of the molecules, which is one important parameter to predict the interaction with lipid membranes. While all four molecules tend to embed in a similar region of the lipid membrane, their presence has different impacts on membrane structure and dynamics. Most notably, sunitinib, exhibiting the lowest log p value of the four inhibitors, effectively influences membrane integrity, while the others do not. This shows that the estimation of the effect of drug molecules on lipid membranes can be rather complex. In this context, experimental studies on lipid membranes are necessary to (i) identify drugs that may disturb membranes and (ii) characterize drug–membrane interactions on a molecular level. Such knowledge is important for understanding the efficacy and potential side effects of respective drugs.

1 October 2021 in Biophysical Chemistry
Verified
Journal Article
Open access
LNLeonie C. Naßwetter
Leonie C. Naßwetter
MFMarkus Fischer
Markus Fischer
HSHolger A Scheidt
Holger A Scheidt
Heiko HeerklotzHeiko Heerklotz
Heiko Heerklotz
Many newly developed drugs suffer from poor water solubility and low bioavailability and hence, need special formulation vehicles like vesicular or micellar drug delivery systems. The knowledge of their membrane-water partition coefficient K becomes critical as is governs drug loading and release from the vehicle, as well as absorption into the body. The dilemma is that measuring K is particularly challenging for these very compounds. Here we establish a strategy to resolve this problem. We added DMSO to shift K and solubility into a convenient range and extrapolated these results back to zero-DMSO. Isothermal titration calorimetry revealed that logK of the kinase inhibitor Lapatinib decreased proportionally to DMSO content (2.5 - 20v%) with a slope of -1/20v% (m value = 28 kJ/mol). This implies a K of 84 mM-1 in DMSO-free buffer. This strategy should be transferable to other poorly soluble drugs and further detection methods.

3 August 2022 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
MFMarkus Fischer
Markus Fischer
BSBenedikt Schwarze
Benedikt Schwarze
NRNikola Ristic
Nikola Ristic
HSHolger A Scheidt
Holger A Scheidt

1 December 2020 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
MFMarkus Fischer
Markus Fischer
MLMeike Luck
Meike Luck
MWMaximilian Werle
Maximilian Werle
HSHolger A Scheidt
Holger A Scheidt
PMPeter Müller
Peter Müller
Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19. While the specific effects of ruxolitinib on Janus kinases (JAK) is comparatively well investigated, its (unspecific) impact on membranes has not been studied in detail so far. Therefore, we characterized the interaction of this drug with lipid membranes employing different biophysical approaches. Ruxolitinib incorporates into the glycerol region of lipid membranes causing an increase in disorder of the lipid chains. This binding, however, has only marginal influence on the structure and integrity of membranes as found by leakage and permeation assays.

1 September 1998 in Endoscopy
Verified
Journal Article
Open access
PDF file
MFM. Fischer
M. Fischer
JPJ. Papp
J. Papp
JKJanina Kulka
Janina Kulka
MZM. Zsiray
M. Zsiray
PKP. Kempler
P. Kempler
FSF. Szalay
F. Szalay